Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Trends in antimicrobial management of gonorrhoea by general practitioners in Amsterdam, the Netherlands, between 2010 and 2016: a cross-sectional study.

van Amerongen R, Gazendam RP, van Bergen JEAM.

BMC Fam Pract. 2019 Jan 15;20(1):12. doi: 10.1186/s12875-018-0900-9.

2.

Wnt signalling: conquering complexity.

Wiese KE, Nusse R, van Amerongen R.

Development. 2018 Jun 26;145(12). pii: dev165902. doi: 10.1242/dev.165902. Review.

3.

Oncogenic transformation of lung cells results in distinct exosome protein profile similar to the cell of origin.

Lobb RJ, Hastie ML, Norris EL, van Amerongen R, Gorman JJ, Möller A.

Proteomics. 2017 Dec;17(23-24). doi: 10.1002/pmic.201600432. Epub 2017 Sep 15.

PMID:
28722786
4.

Exosomes derived from mesenchymal non-small cell lung cancer cells promote chemoresistance.

Lobb RJ, van Amerongen R, Wiegmans A, Ham S, Larsen JE, Möller A.

Int J Cancer. 2017 Aug 1;141(3):614-620. doi: 10.1002/ijc.30752. Epub 2017 May 12.

5.

Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis.

van Amerongen RA, Retèl VP, Coupé VM, Nederlof PM, Vogel MJ, van Harten WH.

Ecancermedicalscience. 2016 Oct 28;10:684. eCollection 2016.

6.

Complexity galore: 3D cultures, biomechanics and systems medicine at the eighth ENBDC workshop "Methods in Mammary Gland Development and Cancer".

Lloyd-Lewis B, van de Moosdijk AA, Bentires-Alj M, Clarke RB, van Amerongen R.

Breast Cancer Res. 2016 Nov 25;18(1):115.

7.

Lineage Tracing of Mammary Stem and Progenitor Cells.

van de Moosdijk AA, Fu NY, Rios AC, Visvader JE, van Amerongen R.

Methods Mol Biol. 2017;1501:291-308.

PMID:
27796960
8.

Identification of reliable reference genes for qRT-PCR studies of the developing mouse mammary gland.

van de Moosdijk AA, van Amerongen R.

Sci Rep. 2016 Oct 18;6:35595. doi: 10.1038/srep35595.

9.

Generating Cellular Diversity and Spatial Form: Wnt Signaling and the Evolution of Multicellular Animals.

Loh KM, van Amerongen R, Nusse R.

Dev Cell. 2016 Sep 26;38(6):643-55. doi: 10.1016/j.devcel.2016.08.011. Review.

10.

PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma.

Boelens MC, Nethe M, Klarenbeek S, de Ruiter JR, Schut E, Bonzanni N, Zeeman AL, Wientjens E, van der Burg E, Wessels L, van Amerongen R, Jonkers J.

Cell Rep. 2016 Aug 23;16(8):2087-2101. doi: 10.1016/j.celrep.2016.07.059. Epub 2016 Aug 11.

11.

Construction and Experimental Validation of a Petri Net Model of Wnt/β-Catenin Signaling.

Jacobsen A, Heijmans N, Verkaar F, Smit MJ, Heringa J, van Amerongen R, Feenstra KA.

PLoS One. 2016 May 24;11(5):e0155743. doi: 10.1371/journal.pone.0155743. eCollection 2016.

12.

CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia.

Kersten B, Valkering M, Wouters R, van Amerongen R, Hanekamp D, Kwidama Z, Valk P, Ossenkoppele G, Zeijlemaker W, Kaspers G, Cloos J, Schuurhuis GJ.

Br J Haematol. 2016 Apr;173(2):219-35. doi: 10.1111/bjh.13941. Epub 2016 Jan 27.

PMID:
26814163
13.

The seventh ENBDC workshop on methods in mammary gland development and cancer.

Glukhova MA, Hynes N, Vivanco Md, van Amerongen R, Clarke RB, Bentires-Alj M.

Breast Cancer Res. 2015 Sep 2;17:119. doi: 10.1186/s13058-015-0629-5.

14.

Lineage Tracing in the Mammary Gland Using Cre/lox Technology and Fluorescent Reporter Alleles.

van Amerongen R.

Methods Mol Biol. 2015;1293:187-211. doi: 10.1007/978-1-4939-2519-3_11.

PMID:
26040689
15.

Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy.

Kemper K, de Goeje PL, Peeper DS, van Amerongen R.

Cancer Res. 2014 Nov 1;74(21):5937-41. doi: 10.1158/0008-5472.CAN-14-1174. Epub 2014 Oct 15. Review.

16.

The influence of tamoxifen on normal mouse mammary gland homeostasis.

Shehata M, van Amerongen R, Zeeman AL, Giraddi RR, Stingl J.

Breast Cancer Res. 2014 Jul 24;16(4):411. doi: 10.1186/s13058-014-0411-0.

17.

In vivo clonal analysis reveals lineage-restricted progenitor characteristics in mammalian kidney development, maintenance, and regeneration.

Rinkevich Y, Montoro DT, Contreras-Trujillo H, Harari-Steinberg O, Newman AM, Tsai JM, Lim X, Van-Amerongen R, Bowman A, Januszyk M, Pleniceanu O, Nusse R, Longaker MT, Weissman IL, Dekel B.

Cell Rep. 2014 May 22;7(4):1270-83. doi: 10.1016/j.celrep.2014.04.018. Epub 2014 May 15.

18.

Bipotent mammary stem cells: now in amazing 3D.

van Amerongen R.

Breast Cancer Res. 2014 Nov 27;16(6):480. doi: 10.1186/s13058-014-0480-0.

19.

The role of Ryk and Ror receptor tyrosine kinases in Wnt signal transduction.

Green J, Nusse R, van Amerongen R.

Cold Spring Harb Perspect Biol. 2014 Feb 1;6(2). pii: a009175. doi: 10.1101/cshperspect.a009175. Review.

20.

Interfollicular epidermal stem cells self-renew via autocrine Wnt signaling.

Lim X, Tan SH, Koh WL, Chau RM, Yan KS, Kuo CJ, van Amerongen R, Klein AM, Nusse R.

Science. 2013 Dec 6;342(6163):1226-30. doi: 10.1126/science.1239730.

21.

Transient, afferent input-dependent, postnatal niche for neural progenitor cells in the cochlear nucleus.

Volkenstein S, Oshima K, Sinkkonen ST, Corrales CE, Most SP, Chai R, Jan TA, van Amerongen R, Cheng AG, Heller S.

Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14456-61. doi: 10.1073/pnas.1307376110. Epub 2013 Aug 12. Erratum in: Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):1760. van Amerongen, Renée [added].

22.

Break the loop, escape the cycle?

van Amerongen R, Berns A.

EMBO J. 2013 Jul 17;32(14):1967-9. doi: 10.1038/emboj.2013.137. Epub 2013 Jun 7. No abstract available.

23.

Lineage tracing with Axin2 reveals distinct developmental and adult populations of Wnt/β-catenin-responsive neural stem cells.

Bowman AN, van Amerongen R, Palmer TD, Nusse R.

Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7324-9. doi: 10.1073/pnas.1305411110. Epub 2013 Apr 15.

24.

Tympanic border cells are Wnt-responsive and can act as progenitors for postnatal mouse cochlear cells.

Jan TA, Chai R, Sayyid ZN, van Amerongen R, Xia A, Wang T, Sinkkonen ST, Zeng YA, Levin JR, Heller S, Nusse R, Cheng AG.

Development. 2013 Mar;140(6):1196-206. doi: 10.1242/dev.087528.

25.

Celebrating 30 years of Wnt signaling.

Verkaar F, Cadigan KM, van Amerongen R.

Sci Signal. 2012 Dec 11;5(254):mr2. doi: 10.1126/scisignal.2003714.

PMID:
23233527
26.

Frat2 mediates the oncogenic activation of Rac by MLL fusions.

Walf-Vorderwülbecke V, de Boer J, Horton SJ, van Amerongen R, Proost N, Berns A, Williams O.

Blood. 2012 Dec 6;120(24):4819-28. doi: 10.1182/blood-2012-05-432534. Epub 2012 Oct 16.

27.

Alternative Wnt pathways and receptors.

van Amerongen R.

Cold Spring Harb Perspect Biol. 2012 Oct 1;4(10). pii: a007914. doi: 10.1101/cshperspect.a007914. Review.

28.

Derivation of a pediatric growth curve for inferior vena caval diameter in healthy pediatric patients: brief report of initial curve development.

Haines EJ, Chiricolo GC, Aralica K, Briggs WM, Van Amerongen R, Laudenbach A, O'Rourke K, Melniker L.

Crit Ultrasound J. 2012 May 28;4(1):12. doi: 10.1186/2036-7902-4-12.

29.

Developmental stage and time dictate the fate of Wnt/β-catenin-responsive stem cells in the mammary gland.

van Amerongen R, Bowman AN, Nusse R.

Cell Stem Cell. 2012 Sep 7;11(3):387-400. doi: 10.1016/j.stem.2012.05.023. Epub 2012 Aug 2.

30.

Wnt5a can both activate and repress Wnt/β-catenin signaling during mouse embryonic development.

van Amerongen R, Fuerer C, Mizutani M, Nusse R.

Dev Biol. 2012 Sep 1;369(1):101-14. doi: 10.1016/j.ydbio.2012.06.020. Epub 2012 Jul 4.

31.

Evaluating outcomes associated with a discharge action plan employing single-dose home use of ondansetron in patients with acute gastroenteritis.

Haines E, van Amerongen R, Birkhahn R, Wen W, Gaeta T.

Open Access Emerg Med. 2012 Mar 26;4:1-4. doi: 10.2147/OAEM.S27462. eCollection 2012.

32.

Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways.

van Amerongen R, Nawijn MC, Lambooij JP, Proost N, Jonkers J, Berns A.

Oncogene. 2010 Jan 7;29(1):93-104. doi: 10.1038/onc.2009.310. Epub 2009 Oct 5.

PMID:
19802005
33.

Towards an integrated view of Wnt signaling in development.

van Amerongen R, Nusse R.

Development. 2009 Oct;136(19):3205-14. doi: 10.1242/dev.033910. Review.

34.

Alternative wnt signaling is initiated by distinct receptors.

van Amerongen R, Mikels A, Nusse R.

Sci Signal. 2008 Sep 2;1(35):re9. doi: 10.1126/scisignal.135re9. Review.

PMID:
18765832
35.

Targeted anticancer therapies: mouse models help uncover the mechanisms of tumor escape.

van Amerongen R, Berns A.

Cancer Cell. 2008 Jan;13(1):5-7. doi: 10.1016/j.ccr.2007.12.019. Erratum in: Cancer Cell. 2008 Mar;13(3):287.

36.

Knockout mouse models to study Wnt signal transduction.

van Amerongen R, Berns A.

Trends Genet. 2006 Dec;22(12):678-89. Epub 2006 Oct 11. Review.

PMID:
17045694
37.

TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes?

van Amerongen R, Berns A.

Genes Dev. 2006 Aug 1;20(15):1975-81. Review. No abstract available.

38.

Pediatric nerve agent poisoning: medical and operational considerations for emergency medical services in a large American city.

Foltin G, Tunik M, Curran J, Marshall L, Bove J, van Amerongen R, Cherson A, Langsam Y, Kaufman B, Asaeda G, Gonzalez D, Cooper A.

Pediatr Emerg Care. 2006 Apr;22(4):239-44.

PMID:
16651913
39.

Re-evaluating the role of Frat in Wnt-signal transduction.

van Amerongen R, Berns A.

Cell Cycle. 2005 Aug;4(8):1065-72. Epub 2005 Aug 1. Review.

PMID:
16082208
40.

Use of ultrasonography to identify infants for whom urinary catheterization will be unsuccessful because of insufficient urine volume: validation of the urinary bladder index.

Milling TJ Jr, Van Amerongen R, Melville L, Santiago L, Gaeta T, Birkhahn R, Melniker L.

Ann Emerg Med. 2005 May;45(5):510-3.

PMID:
15855948
41.

Frat is dispensable for canonical Wnt signaling in mammals.

van Amerongen R, Nawijn M, Franca-Koh J, Zevenhoven J, van der Gulden H, Jonkers J, Berns A.

Genes Dev. 2005 Feb 15;19(4):425-30. Epub 2005 Jan 28.

42.

Characterization and functional analysis of the murine Frat2 gene.

van Amerongen R, van der Gulden H, Bleeker F, Jonkers J, Berns A.

J Biol Chem. 2004 Jun 25;279(26):26967-74. Epub 2004 Apr 8.

43.

Patterns in childhood sports injury.

Damore DT, Metzl JD, Ramundo M, Pan S, Van Amerongen R.

Pediatr Emerg Care. 2003 Apr;19(2):65-7.

PMID:
12698027
44.

Selection and characterisation of a phage-displayed human antibody (Fab) reactive to the lung resistance-related major vault protein.

Scheffer GL, Reurs AW, Jutten B, Beiboer SH, van Amerongen R, Schoester M, Wiemer EA, Hoogenboom HR, Scheper RJ.

Br J Cancer. 2002 Mar 18;86(6):954-62.

45.

Reduced rates of gene loss, gene silencing, and gene mutation in Dnmt1-deficient embryonic stem cells.

Chan MF, van Amerongen R, Nijjar T, Cuppen E, Jones PA, Laird PW.

Mol Cell Biol. 2001 Nov;21(22):7587-600.

46.

Severe hypernatremic dehydration and death in a breast-fed infant.

van Amerongen RH, Moretta AC, Gaeta TJ.

Pediatr Emerg Care. 2001 Jun;17(3):175-80. Review.

PMID:
11437141
47.

Pediatric advanced life support training of pediatricians in New Jersey: cause for concern?

van Amerongen R, Klig S, Cunningham F Jr, Sylvester L, Silber S.

Pediatr Emerg Care. 2000 Feb;16(1):13-7.

PMID:
10698136
48.

In vivo analysis of Frat1 deficiency suggests compensatory activity of Frat3.

Jonkers J, van Amerongen R, van der Valk M, Robanus-Maandag E, Molenaar M, Destrée O, Berns A.

Mech Dev. 1999 Nov;88(2):183-94.

49.

Ventricular fibrillation following blunt chest trauma from a baseball.

van Amerongen R, Rosen M, Winnik G, Horwitz J.

Pediatr Emerg Care. 1997 Apr;13(2):107-10. Review.

PMID:
9127418
50.

A look at our new emergency department: the Newark Beth Israel Medical Center, Newark, New Jersey.

Winters JP, Cunningham FJ Jr, van Amerongen R.

J Emerg Nurs. 1994 Aug;20(4):33A-34A. No abstract available.

PMID:
8057601

Supplemental Content

Loading ...
Support Center